Enveric Biosciences Inc

Change company Symbol lookup

Select an option...

ENVB Enveric Biosciences Inc

BKE Buckle Inc

ROP Roper Technologies Inc

ESYJY Easyjet PLC

OGE OGE Energy Corp

ASB-E Associated Banc-Corp

LI Li Auto Inc

IKT Inhibikase Therapeutics Inc

GSIT GSI Technology Inc

AZRE Azure Power Global Ltd

Go

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.